Doorgaan naar hoofdnavigatie
Doorgaan naar zoeken
Ga verder naar hoofdinhoud
Sorteer per
Keyphrases
Neuroblastoma
66%
T Cells
45%
Juvenile Dermatomyositis
43%
Organoids
30%
Disease Activity
26%
Galectin-9 (Gal-9)
26%
CXCL10
24%
MHC Class II
21%
Adoptive Cell Therapy
18%
Single-cell RNA Sequencing (scRNA-seq)
18%
TIGIT
16%
Integrative Analysis
16%
Nectin-2
16%
Tumor
16%
Biomarker Profile
16%
Immune Landscape
16%
High-risk Neuroblastoma
15%
Natural Killer Cells
15%
Tumor Cells
13%
Immunomodulatory
12%
TNF Receptor 2 (TNFR2)
12%
B Cells
11%
Localized Scleroderma
11%
CCL18
11%
Pediatric Tumors
11%
Solid Tumors
10%
Endothelial Cells
10%
Killing Assay
10%
Interferon Signature
10%
Patient-derived Organoids
10%
Pediatric
10%
Serum Levels
10%
Systemic Autoimmune Diseases
9%
Tissue Inflammation
9%
Inflammation
9%
Endothelial Dysfunction
9%
Autoantibodies
9%
Pediatric Oncology
9%
T-cell Mediated
8%
Working Diagnosis
8%
Tissue Residency
8%
Treatment Response
8%
Tumor Microenvironment
8%
Three-dimensional Modeling
8%
Microenvironment
8%
Three-dimensional (3D)
8%
Therapy Efficacy
8%
Cytotoxicity Assay
8%
Connective Tissue Disease
8%
Cardiorespiratory Fitness
8%
Medicine and Dentistry
Ganglioneuroblastoma
100%
T Cell
57%
Immunotherapy
51%
Organoid
47%
Neoplasm
31%
Tumor Microenvironment
24%
Solid Malignant Neoplasm
22%
In Vitro
20%
RNA Sequence
20%
Cytotoxicity
19%
Tumor Cell
18%
Pediatrics
18%
Migration Inhibition Factor
16%
Immunosuppressive Drug
15%
Natural Killer Cell
14%
Chimeric Antigen Receptor T-Cell
12%
Secretion (Process)
12%
Neuroblastoma Cell Line
12%
Cell Therapy
11%
Childhood Cancer
11%
B Cell
11%
Pediatric Cancer
10%
Transcriptomics
10%
Immunity
9%
Midkine
9%
Chimeric Antigen Receptor T-Cell Immunotherapy
9%
Tumor
9%
Immunogenicity
9%
High Throughput Screening
9%
Immunocompetent Cell
8%
Dinutuximab
8%
T Lymphocyte Receptor
8%
Cytotoxicity Assay
8%
Cell Lineage
8%
Juvenile Dermatomyositis
8%
Cardiorespiratory
8%
Pontine Glioma
8%
Personalized Medicine
8%
Immunoglobulin A
8%
Neutrophil
8%
Drug Sensitivity
8%
Tertiary Lymphoid Structure
8%
Tumor Infiltrating Lymphocyte
7%
Major Histocompatibility Complex
6%
Survival Rate
5%
Histone Deacetylase Inhibitor
5%
Immunology and Microbiology
T Cell
68%
Immunotherapy
42%
Dermatomyositis
40%
Organoid
31%
Cytotoxicity
30%
RNA Sequence
28%
Ecalectin
23%
Natural Killer Cell
18%
Tumor Cell
18%
Chimeric Antigen Receptor T-Cell
17%
CXCL10
16%
interferon
16%
Immunosuppressive Drug
16%
Migration Inhibition Factor
16%
Immune Landscape
16%
B Cell
15%
In Vitro
14%
T Cell Receptor
13%
Autoantibodies
11%
Secretion (Process)
11%
CCL18
11%
Localized Scleroderma
11%
Blood Level
11%
Cell Interaction
10%
Midkine
9%
Tumor Necrosis Factor Receptor 2
9%
Regulatory T Cell
9%
Immunoglobulin A
9%
Systemic Autoimmune Disease
9%
Programmed Death-Ligand 1
8%
Cell Lineage
8%
Immunogenicity
8%
Systemic Lupus Erythematosus
8%
Antiphospholipid Syndrome
8%
5' Nucleotidase
8%
Connective Tissue
8%
Oxygen Consumption
8%
Autoimmunity
8%
STAT3
8%
Prednisone
8%
Neutrophil
8%
CD47
8%
Magnetic Resonance Imaging
8%
Tertiary Lymphoid Structure
8%
CD69
7%
Major Histocompatibility Complex
7%
Survival Rate
6%
Dinutuximab
6%
Eosinophilic Fasciitis
6%
Myeloid
6%
